
CJ Medical is a UK-based provider of innovative medical devices and solutions that support better patient outcomes and healthcare efficiency. The company partners with leading manufacturers to supply hospitals, clinics, and healthcare professionals with products that are safe, effective, and compliant with the highest quality standards.
With a strong commitment to sustainability and responsible sourcing, CJ Medical recognises the importance of understanding and reducing the environmental impacts of its product portfolio. This Product Carbon Footprint (PCF) study represents a proactive step towards transparency, accountability, and continuous improvement in environmental performance.
Carbon Sense and The Way To Do Ltd were commissioned to complete a Product Carbon Footprint analysis for a selection of CJ Medical's key product lines, covering nine medical devices sourced from international manufacturing partners.
Medical devices present a complex challenge for sustainability analysis. Products are often manufactured overseas, shipped via multiple transport modes, packaged in clinical-grade materials, and must be incinerated as clinical waste at end of life, each stage carrying its own carbon burden.
CJ Medical wanted to build a clear, evidence-based picture of the carbon emissions embedded across its core product range, and to understand how procurement and logistics decisions could influence overall environmental performance.
A key driver was the NHS Evergreen Sustainable Supplier Assessment, the NHS's framework for evaluating the sustainability credentials of its supply chain partners. Meeting the minimum requirements of Evergreen Level 1 is increasingly expected of suppliers to NHS, and CJ Medical recognised that credible product-level carbon data would be central to satisfying those requirements and to building a platform for further progress.
The key objectives were to:
Carbon Sense and The Way To Do Ltd carried out a Product Carbon Footprint (PCF) assessment across nine of CJ Medical's key product lines, following a structured cradle-to-grave methodology aligned with GWP100 (Global Warming Potential over 100 years) and using CO₂e as the primary impact indicator.
The assessment was built from primary data provided by CJ Medical's suppliers and sustainability team, supplemented by industry-standard emissions factor databases. Each product was assessed across five lifecycle stages:

A key component of the analysis was a comparative assessment of inward shipping methods. For products currently transported by air freight, the study modelled the carbon impact of switching to cargo ship, providing CJ Medical with actionable data on potential emission reductions achievable through logistics optimisation alone.
The use phase was considered negligible for all nine products, as none contain electronic or powered components,meaning end-of-life incineration as clinical waste represents the final significant emission source in each product's lifecycle.
